In what year did keytruda gain fda approval for lung cancer treatment?

Keytruda received its first FDA approval for lung cancer treatment in 2015.

How long did Keytruda's approval for lung cancer take from clinical trials?

Keytruda's approvals for lung cancer have come through multiple pathways. The 2015 approval rested on a single-arm study in patients previously treated for metastatic non-small cell lung cancer. Later approvals relied on larger trials that included survival data.

When does Keytruda's exclusivity for lung cancer indications expire?

Keytruda holds multiple patents and regulatory exclusivities tied to each indication. Overall exclusivity for the drug often runs through the 2030s. The earliest possible generic or biosimilar entry would require overcoming these protections.

What side effects are patients asking about after receiving Keytruda for lung cancer?

Patients frequently report immune-related side effects such as colitis, pneumonitis, and endocrinopathies. These occur because Keytruda blocks the PD-1 pathway, freeing the immune system to attack both cancer cells and healthy tissue.

Why are companies challenging Keytruda's patents?

Companies pursue invalidity challenges through inter partes review at the U.S. Patent and Trademark Office. Results remain mixed. Some claims have been upheld, while others have been invalidated. The core compound patent remains in force.

Can biosimilars enter before Keytruda's patent expire?

No. Current patent thickets and regulatory exclusivities block biosimilar entry until at least the 2030s. Any early entry would require litigation success or voluntary licensing agreements.